Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma
NCT00133302Phase 3Terminated
- Sponsor
- Japan Clinical Oncology Group
- Start
- Feb 1999
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide, doxorubicin, vincristine, prednisone in non-Hodgkin lymphoma (NHL), sponsored by Japan Clinical Oncology Group. Started Feb 1999; status: terminated.
02
Drugs
cyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00133302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133302.